GlassScriptPhysician profile
Andrew J Colman
NPI 1912983131
$8,552.92
in general payments reported to CMS, 2019-2025
51 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what 93% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,145 · 2020: $965 · 2021: $1,364 · 2022: $1,427 · 2023: $1,173 · 2024: $1,279 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,601 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,601.02 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $777.54 | 2019-2024 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $641.39 | 2019-2025 | Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $602.84 | 2019-2022 | |
| Lilly USA, LLC | $538.37 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $474.63 | 2021-2024 | |
| Pfizer INC. | $453.62 | 2019-2025 | |
| Novo Nordisk INC | $378.88 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $351.28 | 2019-2025 | Otezla, Enbrel, Repatha |
| Vanda Pharmaceuticals INC. | $324.84 | 2019-2025 | Hetlioz, Fanapt |
| Astrazeneca Pharmaceuticals LP | $269.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Sumitomo Pharma America, INC. | $264.54 | 2023-2025 | Gemtesa, Aptiom |
| Ucb, INC. | $263.03 | 2021-2024 | Nayzilam, Briviact |
| Novartis Pharmaceuticals Corporation | $244.53 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $243.91 | 2022-2025 | Ingrezza |
| Glaxosmithkline, LLC. | $233.64 | 2019-2025 | Trelegy Ellipta, Arexvy |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Colman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.